Despite a preliminary theory that health insurers could potentially hold too much buyer power, resulting in a loss of quality of consulting and preventative care for consumers, the Competition Commission has expressed support of health insurers in its most recent update of a widespread probe into the UK’s private healthcare sector. A common complaint, according to reports, often involves Bupa, one of the UK’s largest private medical insurers; the CC has received complaints that the insurer’s fee schedule reduces consultation quality and hinders innovation. The Commission has said it has “not seen evidence” of these claims, however. While its update did not come down hard on insurers, the Commission did suggest that there may be cause for concern within the private hospital operators’ sector.
Full Content: Health Investor
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Takes On Prescription Drug Middlemen Over High Insulin Costs
Sep 20, 2024 by
CPI
EU’s Incoming Competition Head Pushes for Policy Shift to Support ‘European Champions
Sep 19, 2024 by
CPI
Google Challenges $217 Million Legal Fee Demand in Privacy Case
Sep 19, 2024 by
CPI
EU Moves to Enforce Apple’s Compliance with New Market Rules
Sep 19, 2024 by
CPI
California Attorney General Bonta Stands Firm Against Albertsons-Kroger Merger
Sep 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Canada & Mexico
Sep 3, 2024 by
CPI
Competitive Convergence: Mexico’s 30-Year Quest for Antitrust Parity with its Northern Neighbor
Sep 3, 2024 by
Francisco Javier Núñez Melgoza
Competition and Digital Markets in North America: A Comparative Study of Antitrust Investigations in Mexico and the United States
Sep 3, 2024 by
Julio Garcia
Recent Antitrust Development in Mexico: COFECE’s Preliminary Report on Amazon and Mercado Libre
Sep 3, 2024 by
Alejandra Palacios Prieto
The Cost of Making COFECE Disappear
Sep 3, 2024 by
Mateo Fernández